Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from BIIB

Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane

Biogen Inc (NASDAQ: BIIB) and Xbrane Biopharma AB have

Benzinga · Feb 8, 2022

Biogen's Aduhelm Approval, Marketing Comes Under FTC, SEC Probes

The Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) have launched two separate investigations into Biogen Inc (NASDAQ: BIIB) and its Alzheimer's med, Aduhelm (aducanumab).

Benzinga · Feb 4, 2022

What 24 Analyst Ratings Have To Say About Biogen

Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings:

Benzinga · Feb 4, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Analyst Ratings For Biogen

Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter:

Benzinga · Feb 4, 2022

Biogen's Alzheimer's Drug Clocks Q4 Sales Of Just $1M, FY22 Earnings Guidance Below Consensus

Biogen Inc (NASDAQ: BIIB) posted Q4 sales of 2.73 billion, beating the consensus of $

Benzinga · Feb 3, 2022

Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab

Biogen Inc (NASDAQ: BIIB) has

Benzinga · Feb 1, 2022

Biogen Sells Biosimilar-Venture Stake To Samsung Biologics For $2.3B

Biogen Inc (NASDAQ: BIIB) is selling its stake in a pharmaceutical joint venture with the South Korean conglomerate Samsung for $2.3 billion.

Benzinga · Jan 28, 2022

Read news from The Economist, FT, and more,
with one subscription

1 … 3 4 5 6

Coverage From

Organisations

Federal Trade Commission

477 stories

Securities and Exchange Commission

From analysis to the latest developments in health,
read the most diverse news in one place.

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.